LEAWOOD, Kan., Jan. 18, 2018 /PRNewswire/ -- Aratana
Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company
focused on the licensing, development and commercialization of
innovative therapeutics for dogs and cats, today announced
GALLIPRANT® (grapiprant tablets) was named Animal
Pharm's Best Companion Animal Product for 2017.
Galliprant was made commercially available to veterinarians in
January 2017 through a license and
collaboration agreement with Elanco Animal Health, a division of
Eli Lilly and Company (NYSE: LLY). Galliprant provides targeted
pain control from the earliest diagnosed stages of canine
osteoarthritis and is the first piprant (a prostaglandin receptor
antagonist) approved for use in veterinary medicine. It represents
the evolution of canine anti-inflammatory drugs by specifically
blocking the prostaglandin EP4 receptor, which is the primary
mediator of OA pain and inflammation.1
This is the fourth consecutive year Aratana has been honored
with an award from Animal Pharm. Aratana was named Best
Company in North America 2016
based on the FDA approval of three innovative therapeutics,
GALLIPRANT® (grapiprant tablets), ENTYCE®
(capromorelin oral solution) and NOCITA® (bupivacaine
liposome injectable suspension), as well as its evolution to a
commercial company.
Indication
Galliprant is indicated for the control of
pain and inflammation associated with osteoarthritis in dogs.
Important Safety Information
Not for use in
humans. For use in dogs only. Keep this and all medications out of
reach of children and pets. Store out of reach of dogs and other
pets in a secured location in order to prevent accidental ingestion
or overdose. Do not use in dogs that have a hypersensitivity to
grapiprant. If Galliprant is used long term, appropriate monitoring
is recommended. Concomitant use of Galliprant with other
anti-inflammatory drugs, such as COX-inhibiting NSAIDs or
corticosteroids, should be avoided. Concurrent use with other
anti-inflammatory drugs or protein-bound drugs has not been
studied. The safe use of Galliprant has not been evaluated in dogs
younger than 9 months of age and less than 8 lbs. (3.6 kg), dogs
used for breeding, pregnant or lactating dogs, or dogs with cardiac
disease. The most common adverse reactions were vomiting, diarrhea,
decreased appetite, and lethargy. For full prescribing information
call 1-888-545-5973.
About Aratana Therapeutics
Aratana Therapeutics is a
pet therapeutics company focused on licensing, developing and
commercializing innovative therapeutics for dogs and cats. Aratana
believes that it can leverage the investment in the human
biopharmaceutical industry to bring therapeutics to dogs and cats
in a capital and time efficient manner. The company's pipeline
includes therapeutic candidates for the potential treatment of
pain, inappetence, viral diseases, allergy, cancer and other
serious medical conditions. Aratana believes the development and
commercialization of these therapeutics will permit veterinarians
and pet owners to manage pets' medical needs safely and
effectively, resulting in longer and improved quality of life for
pets. For more information, please visit www.aratana.com.
Contacts
For investor
inquires:
Craig
Tooman
ctooman@aratana.com
(913) 353-1026
For media inquiries:
Rachel Reiff
rreiff@aratana.com
(913) 353-1050
References
- Kirkby Shaw, K., Rausch-Derra,
L., and Rhodes, L. 2016. "Grapiprant: an EP4 prostaglandin receptor
antagonist and novel therapy for pain and inflammation." Vet. Med.
Sci. 2:3-9.
View original content with
multimedia:http://www.prnewswire.com/news-releases/galliprant-grapiprant-tablets-named-best-companion-animal-product-for-2017-300584391.html
SOURCE Aratana Therapeutics